| P50 | author | Oliver FitzGerald | Q90114816 |
| P2093 | author name string | D. Robertson | |
| | B. Freundlich | |
| | J. C. Prinz | |
| | J. Foehl | |
| | R. Pedersen | |
| | R. I. Boggs | |
| | C. T. Molta | |
| P2860 | cites work | Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression | Q80330608 |
| | Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension | Q81730686 |
| | A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis | Q83171750 |
| | EuroQol--a new facility for the measurement of health-related quality of life | Q29547873 |
| | Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality | Q33723592 |
| | Psoriatic arthritis assessment tools in clinical trials | Q35579462 |
| | Assessment of patients with psoriatic arthritis: a review of currently available measures | Q35632604 |
| | Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis | Q35834819 |
| | The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. | Q36400865 |
| | Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology | Q36594224 |
| | Psoriasis comorbidities | Q37084274 |
| | Psoriatic arthritis: therapeutic principles | Q37255466 |
| | Treatment recommendations for psoriatic arthritis. | Q37284516 |
| | A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. | Q42627575 |
| | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 |
| | Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. | Q52905765 |
| | Psoriatic arthritis | Q61790163 |
| | Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis | Q73810982 |
| | Comparison of disability and quality of life in rheumatoid and psoriatic arthritis | Q74385099 |
| | Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? | Q77341371 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriatic arthritis | Q511097 |
| | quality of life | Q13100823 |
| P304 | page(s) | 559-564 | |
| P577 | publication date | 2010-09-14 | |
| P1433 | published in | Journal of the European Academy of Dermatology and Venereology | Q15760872 |
| P1476 | title | Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial | |
| P478 | volume | 25 | |